Etanercept/celecoxib on improving MRI inflammation of active ankylosing spondylitis: A multicenter, open-label, randomized clinical trial.

塞来昔布 医学 依那西普 强直性脊柱炎 巴斯代人 内科学 骶髂关节 胃肠病学 磁共振成像 脊柱炎
作者
Liudan Tu,Minjing Zhao,Xiaohong Wang,Qingcong Kong,Zena Chen,Qiujing Wei,Qiuxia Li,Qinghong Yu,Zhizhong Ye,Shuangyan Cao,Zhimin Lin,Zetao Liao,Qing Lv,Jun Qi,Ou Jin,Yunfeng Pan,Jieruo Gu
出处
期刊:Frontiers in Immunology [Frontiers Media SA]
卷期号:13: 967658-967658
标识
DOI:10.3389/fimmu.2022.967658
摘要

To investigate the efficacy and safety of clinical, magnetic resonance imaging (MRI) changes in active ankylosing spondylitis (AS) patients with etanercept and celecoxib alone/combined treatment.A randomized controlled trial was conducted in three medical centers in China. Adult AS patients with BASDAI ≥4 or ASDAS ≥2.1, CRP >6 mg/L, or ESR 28 mm/1st hour were randomly assigned (1:1:1 ratio) to celecoxib 200 mg bid or etanercept 50 mg qw or combined therapy for 52 weeks. The primary outcomes were SPARCC change of the sacroiliac joint (SIJ) and spine and the proportion of patients achieving ASAS20 response at 52 weeks.Between September 2014 and January 2016, we randomly assigned 150 patients (mean age, 32.4 years; mean disease duration, 109 months), and 133 (88.6%) completed the study. SPARCC inflammation scores of the SIJ and spine decreased in the three groups, and significant differences were found between the combined group and the celecoxib group [between-group difference: -6.33, 95% CI (-10.56, -2.10) for SIJ; -9.53, 95% CI (-13.73, -5.33) for spine] and between the etanercept group and the celecoxib group [between-group difference: -5.02, 95% CI (-9.29, -0.76) for SIJ; -5.80, 95% CI (-10.04, -1.57) for spine]. The ASAS20 response rates were 44%, 58%, and 84% in the celecoxib, etanercept, and combined groups, respectively, and a significant difference was only found between the combined and the celecoxib groups.Etanercept with or without celecoxib decreases inflammation detected by MRI at 1 year compared to celecoxib alone in active AS patients. The combination of etanercept and celecoxib was superior to celecoxib alone for the primary clinical response.ClinicalTrials.gov, identifier NCT01934933.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
岛屿发布了新的文献求助10
4秒前
6秒前
7秒前
Mian发布了新的文献求助10
11秒前
Akim应助科研通管家采纳,获得10
11秒前
FashionBoy应助科研通管家采纳,获得50
11秒前
SciGPT应助科研通管家采纳,获得10
11秒前
爆米花应助科研通管家采纳,获得10
12秒前
桐桐应助科研通管家采纳,获得10
12秒前
ding应助科研通管家采纳,获得10
12秒前
顾矜应助科研通管家采纳,获得10
12秒前
科研通AI2S应助科研通管家采纳,获得10
12秒前
Gergeo应助科研通管家采纳,获得20
12秒前
12秒前
缥缈南风发布了新的文献求助10
12秒前
13秒前
zhilianghui0807完成签到 ,获得积分10
15秒前
123关闭了123文献求助
15秒前
Mian完成签到,获得积分10
16秒前
贪玩的友灵完成签到 ,获得积分10
16秒前
领导范儿应助过时的起眸采纳,获得10
16秒前
lyl发布了新的文献求助10
16秒前
此话当真发布了新的文献求助20
16秒前
幽默的忆霜完成签到 ,获得积分10
17秒前
颉嘉乐完成签到,获得积分10
17秒前
liu完成签到,获得积分10
20秒前
小鸟芋圆露露完成签到 ,获得积分10
23秒前
华仔应助别急我先送采纳,获得10
25秒前
FashionBoy应助猩心采纳,获得10
25秒前
bkagyin应助852采纳,获得10
26秒前
oceanao应助陈大侠采纳,获得10
26秒前
FashionBoy应助22222采纳,获得10
28秒前
zwhy发布了新的文献求助10
29秒前
31秒前
31秒前
自然的绿草完成签到 ,获得积分10
36秒前
猩心发布了新的文献求助10
37秒前
852发布了新的文献求助10
37秒前
zhang完成签到,获得积分10
37秒前
lyl完成签到,获得积分10
38秒前
高分求助中
Evolution 10000
Becoming: An Introduction to Jung's Concept of Individuation 600
Ore genesis in the Zambian Copperbelt with particular reference to the northern sector of the Chambishi basin 500
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 500
The Kinetic Nitration and Basicity of 1,2,4-Triazol-5-ones 440
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3164170
求助须知:如何正确求助?哪些是违规求助? 2814884
关于积分的说明 7906945
捐赠科研通 2474500
什么是DOI,文献DOI怎么找? 1317533
科研通“疑难数据库(出版商)”最低求助积分说明 631841
版权声明 602228